Share this post on:

Product: Molidustat

EPLIN RNAi Summary

Specificity
epithelial protein lost in neoplasm beta (EPLIN), mRNA
Gene
LIMA1

Applications/Dilutions

Application Notes
This RNAi causes protein knockdown.

Packaging, Storage & Formulations

Storage
Store at -20C. Avoid freeze-thaw cycles.

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for EPLIN RNAi

  • 1110021C24Rik
  • Epithelial protein lost in neoplasm
  • EPLINepithelial protein lost in neoplasm beta
  • FLJ38853
  • LIM domain and actin binding 1
  • MGC131726
  • SREBP3LIM domain and actin-binding protein 1
  • sterol regulatory element binding protein 3

Background

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

PMID: 2840296

Share this post on:

Author: Potassium channel